Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGNYTE-3: VO + Nivolumab in Advanced Melanoma
NCT06264180Phase 3Recruiting
- Sponsor
- Replimune Group, Inc.
- Start
- Jul 2024
- Primary completion
- Sep 2030
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 7
01
Overview
A Phase 3 trial of vusolimogene oderparepvec in melanoma, sponsored by Replimune Group, Inc.. Started Jul 2024; status: recruiting.
02
Drugs
vusolimogene oderparepvec
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06264180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06264180.